EFEMP2
protein-codingEGF containing fibulin extracellular matrix protein 2, the group of Fibulins
Gene summary
A large number of extracellular matrix proteins have been found to contain variations of the epidermal growth factor (EGF) domain and have been implicated in functions as diverse as blood coagulation, activation of complement and determination of cell fate during development. The protein encoded by this gene contains four EGF2 domains and six calcium-binding EGF2 domains. This gene is necessary for elastic fiber formation and connective tissue development. Defects in this gene are cause of an autosomal recessive cutis laxa syndrome. Alternatively spliced transcript variants have been identified for this gene. [provided by RefSeq, Jan 2011]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~7.2 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0017818
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0019572
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0013754
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0005396
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0013754
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0013754
Submitter: ClinGen
*EFEMP2* has been reported in association with autosomal recessive cutis laxa type 1B (ARCL1B) in at least 49 individuals (Loeys B, De Paepe A, Urban Z GeneReviews, 2023). This gene-disease relationship was originally classified as moderate by the HTAAD GCEP in 12/22/2016. Clinical phenotypes of ARCL1B include cutis laxa, arterial tortuosity, aortic aneurysm, diaphragmatic hernia, emphysema, craniofacial features, and musculoskeletal abnormalities. Phenotype severity ranges from embryonic/perinatal lethality to asymptomatic patients with aortic aneurysm found on imaging. Seven variants (missense and frameshift) reported in 6 probands in 6 publications (PMIDs: 22440127, 30140196, 22070778, 28673110, 23532871, 20389311) are included in this curation. The mechanism of pathogenicity is proposed to be loss of function. This gene-disease association is also supported by experimental evidence including protein expression in the aorta (PMID:23715323) and protein interaction with *LOX*, which is also associated with aortic aneurysm (PMID:19855011). Finally, multiple KO mouse models have recapitulated phenotypes of ARCL1B including emphysema, arterial tortuosity, and aortic aneurysm (PMIDs: 16478991, 17293478). In summary, *EFEMP2* is definitively associated with autosomal recessive cutis laxa type 1B and aortic aneurysm. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. The evidence summary was updated by the Heritable Thoracic Aortic Aneurysm and Dissection subgroup of the Hereditary Cardiovascular Disease Gene Curation Expert Panel on 8/23/2024.
Inheritance Pattern: AR
Disease ID:MONDO:0013754
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0013754
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0013754
Submitter: G2P
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Dermatologic; Musculoskeletal; Pulmonary
Intervention: Cardiovascular
Rationale: Manifestations can include cardiovascular anomalies, including aortic dilatation and aortic aneurysms, and surveillance may allow early detection and management (eg, with beta-blockers and angiotensin-receptor inhibitors), which can decrease morbidity and mortality; Cigarette smoking should be avoided due to risk of exacerbation of pulmonary manifestations (including emphysema)
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to EFEMP2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_016938.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 6 | 188 | 3 | 197 | ||
| missense | 7 | 8 | 251 | 11 | 277 | |
| nonsense | 2 | 4 | 6 | |||
| start loss | 0 | |||||
| frameshift | 13 | 3 | 1 | 17 | ||
| splice donor/acceptor (+/-2bp) | 2 | 9 | 11 | |||
| Total | 24 | 24 | 258 | 199 | 3 | 508 |
Highest pathogenic variant AF is 0.000042752996
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_058634.4 | 10 | MANE Select | |
| Ensembl | ENSP00000309953.6 | 10 | MANE Select | |
| Ensembl | ENSP00000432191.1 | 2 | Standard | |
| Ensembl | ENSP00000435419.1 | 5 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Extracellular matrix organization
- Molecules associated with elastic fibres
- Elastic fibre formation
Biological Process
- elastic fiber assembly
Molecular Function
- extracellular matrix structural constituent
- calcium ion binding
- protein binding
Cellular Component
- extracellular region
- basement membrane
- collagen-containing extracellular matrix
- extracellular exosome
- extracellular vesicle
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000307998
- Coding exons
- 10
- Length
- 7152
- Individuals with no LoFs
- 125727
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 19
- Defined
- 125746
- p
- 0.0000756
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.976 | 236 | 282 | 0.836 | 0.0000203 | 2896 |
| Missense (PolyPhen) | 73 | 105.53 | 0.69172 | 1105 | ||
| Synonymous | -1.70 | 142 | 118 | 1.20 | 0.00000913 | 856 |
| Loss of Function | 3.03 | 8 | 24.0 | 0.333 | 0.00000113 | 268 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00025 | 0.00025 | rare |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00033 | 0.00033 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000053 | 0.000053 | rare |
| South Asian | 0.000033 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Disease
- DISEASE: Cutis laxa, autosomal recessive, 1B (ARCL1B) [MIM:614437]: A connective tissue disorder characterized by loose, hyperextensible skin with decreased resilience and elasticity leading to a premature aged appearance. Face, hands, feet, joints, and torso may be differentially affected. The clinical spectrum of autosomal recessive cutis laxa is highly heterogeneous with respect to organ involvement and severity. ARCL1B features include emphysema, lethal pulmonary artery occlusion, aortic aneurysm, cardiopulmonary insufficiency, birth fractures, arachnodactyly, and fragility of blood vessels. {ECO:0000269|PubMed:16685658, ECO:0000269|PubMed:17937443, ECO:0000269|PubMed:19664000}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.121
Intolerance Scores
- LoFtool
- 0.125
- RVIS EVS
- -0.6
- RVIS percentile EVS
- 18.06
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.452
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |